Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of NTLA-2002 in hereditary angioedema
NL-OMON60993Phase 3Active, not recruiting
- Sponsor
- Intellia Therapeutics
- Start
- Mar 2025
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nexiguran ziclumeran and lonvoguran in hereditary angioedema (HAE), sponsored by Intellia Therapeutics. Primary endpoint: Time-normalized number of investigator-confirmed hereditary angioedema attacks from Week 5 through Week 28. Started Mar 2025; status: active, not recruiting.
02
Drugs
nexiguran ziclumeranlonvoguran
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NL-OMON60993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60993.